Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?
Launched by MEDICAL UNIVERSITY OF WARSAW · Mar 23, 2021
Trial Information
Current as of June 13, 2025
Terminated
Keywords
ClinConnect Summary
About 5% of all patients infected with the SARS-CoV-2 virus require treatment in the ICU. The main reason for admission to the ICU is acute hypoxemic respiratory failure, which in most cases is associated with the need for mechanical ventilation. The progression of lung damage affects not only alveoli but also endothelium of the pulmonary vessels. Occurring endotheliopathy is caused by direct infection with SARS-CoV-2 virus and activation of the immune system leading to an increased inflammatory reaction. Damage to the endothelium barrier with concomitant cytokine storm lead to activation o...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age ≥ 18 years
- • polymerase chain reaction (PCR) confirmed COVID-19
- • severe stage of pneumonia caused by SARS-CoV-2 requiring oxygen therapy
- • informed consent to participate in the study
- Exclusion Criteria:
- • qualification to palliative care
- • life expectancy \< 48 h
- • mechanical ventilation at the beginning of the hospitalization
- • transfer from other ICU
- • pregnancy
About Medical University Of Warsaw
The Medical University of Warsaw is a leading academic institution dedicated to advancing healthcare through innovative research and education. Renowned for its commitment to excellence in medical training and clinical practice, the university actively engages in a diverse range of clinical trials aimed at improving patient outcomes and enhancing medical knowledge. With a robust infrastructure and a multidisciplinary team of experts, the Medical University of Warsaw fosters collaboration in the development of novel therapies and interventions, contributing significantly to the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warszawa, , Poland
Patients applied
Trial Officials
Paweł Zatorski, MD
Principal Investigator
Medical University of Warsaw
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials